Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in New Mexico: - University of New Mexico Cancer Center — Albuquerque, New Mexico
- Presbyterian Kaseman Hospital — Albuquerque, New Mexico
- Memorial Medical Center-Las Cruces — Las Cruces, New Mexico
- Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in New Mexico: - University of New Mexico Cancer Center — Albuquerque, New Mexico
- Presbyterian Kaseman Hospital — Albuquerque, New Mexico
- Presbyterian Rust Medical Center/Jorgensen Cancer Center — Rio Rancho, New Mexico
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in New Mexico: - University of New Mexico Cancer Center — Albuquerque, New Mexico
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in New Mexico: - University of New Mexico — Albuquerque, New Mexico
- San Juan Oncology Associates — Farmington, New Mexico
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in New Mexico: - Research Site — Albuquerque, New Mexico
- Research Site — Farmington, New Mexico
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in New Mexico: - Presbyterian Medical Group — Albuquerque, New Mexico
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Sites in New Mexico: - Clinical Trial Site — Farmington, New Mexico
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in New Mexico: - Clinical Trial Site — Santa Fe, New Mexico
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in New Mexico: - University of New Mexico Cancer Center — Albuquerque, New Mexico
Phase 2 Recruiting Industry
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Sponsor: Criterium, Inc.
NCT ID: NCT04567420
Sites in New Mexico: - New Mexico Cancer Care Alliance — Albuquerque, New Mexico
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Mexico: - Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
- University of New Mexico Cancer Center — Albuquerque, New Mexico
- Lovelace Women's Hospital — Albuquerque, New Mexico
- Presbyterian Kaseman Hospital — Albuquerque, New Mexico
- Memorial Medical Center-Las Cruces — Las Cruces, New Mexico
NA Recruiting Network
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to e…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06112613
Sites in New Mexico: - University of New Mexico Cancer Center — Albuquerque, New Mexico
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Mexico: - Massive Bio SYNERGY-AI site — Albuquerque, New Mexico
NA Recruiting Academic/Other
Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for surgeons plus patient decision aid vs. usu…
Sponsor: Beth Israel Deaconess Medical Center
NCT ID: NCT06896474
Sites in New Mexico: - University of New Mexico — Albuquerque, New Mexico